File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells.

TitleSpecific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells.
Authors
Issue Date2003
PublisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ijo/
Citation
International Journal Of Oncology, 2003, v. 23 n. 1, p. 113-119 How to Cite?
AbstractCyclooxygenase (COX-2) has been recently suggested to play a role in hepatocarcinogenesis. However, the exact pathway by which COX-2 affects the growth of hepatocellular carcinoma (HCC) is not clear. This study investigated the effects of a specific COX-2 inhibitor, NS-398, on the cell proliferation and apoptosis of COX-2-expressing and non-expressing HCC cell lines. In addition, the modulatory effect of NS-398 on apoptosis-regulating gene expression was examined. Semi-quantitative/quantitative reverse transcription-polymerase chain reaction and Western blot showed that Hep3B and HKCI-4 cells expressed COX-2 mRNA and protein, but HepG2 cells did not. NS-398 suppressed cell proliferation and induced apoptosis in the two COX-2-expressing cell lines in a dose-dependent manner, but not in HepG2 cells. Fas ligand mRNA and protein expression were increased by the treatment with NS-398 (10 micro M) in COX-2-expressing cell lines. The expressions of Fas and Bcl-2 family genes (Bax, Bcl-2, Bcl-xL, Bcl-xS) were not affected by NS-398 treatment in all three cell lines. In conclusion, specific COX-2 inhibitor suppresses cell proliferation and induces apoptosis in HCC cell lines that express COX-2. Our finding suggests that COX-2 inhibition may offer a new approach for HCC chemoprevention.
Persistent Identifierhttp://hdl.handle.net/10722/162735
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.099
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCheng, ASen_US
dc.contributor.authorChan, HLen_US
dc.contributor.authorLeung, WKen_US
dc.contributor.authorWong, Nen_US
dc.contributor.authorJohnson, PJen_US
dc.contributor.authorSung, JJen_US
dc.date.accessioned2012-09-05T05:22:53Z-
dc.date.available2012-09-05T05:22:53Z-
dc.date.issued2003en_US
dc.identifier.citationInternational Journal Of Oncology, 2003, v. 23 n. 1, p. 113-119en_US
dc.identifier.issn1019-6439en_US
dc.identifier.urihttp://hdl.handle.net/10722/162735-
dc.description.abstractCyclooxygenase (COX-2) has been recently suggested to play a role in hepatocarcinogenesis. However, the exact pathway by which COX-2 affects the growth of hepatocellular carcinoma (HCC) is not clear. This study investigated the effects of a specific COX-2 inhibitor, NS-398, on the cell proliferation and apoptosis of COX-2-expressing and non-expressing HCC cell lines. In addition, the modulatory effect of NS-398 on apoptosis-regulating gene expression was examined. Semi-quantitative/quantitative reverse transcription-polymerase chain reaction and Western blot showed that Hep3B and HKCI-4 cells expressed COX-2 mRNA and protein, but HepG2 cells did not. NS-398 suppressed cell proliferation and induced apoptosis in the two COX-2-expressing cell lines in a dose-dependent manner, but not in HepG2 cells. Fas ligand mRNA and protein expression were increased by the treatment with NS-398 (10 micro M) in COX-2-expressing cell lines. The expressions of Fas and Bcl-2 family genes (Bax, Bcl-2, Bcl-xL, Bcl-xS) were not affected by NS-398 treatment in all three cell lines. In conclusion, specific COX-2 inhibitor suppresses cell proliferation and induces apoptosis in HCC cell lines that express COX-2. Our finding suggests that COX-2 inhibition may offer a new approach for HCC chemoprevention.en_US
dc.languageengen_US
dc.publisherSpandidos Publications. The Journal's web site is located at http://www.spandidos-publications.com/ijo/en_US
dc.relation.ispartofInternational journal of oncologyen_US
dc.subject.meshAnnexin A5 - Pharmacologyen_US
dc.subject.meshApoptosisen_US
dc.subject.meshBlotting, Westernen_US
dc.subject.meshCarcinoma, Hepatocellular - Drug Therapy - Pathologyen_US
dc.subject.meshCell Divisionen_US
dc.subject.meshCell Lineen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshCyclooxygenase 2en_US
dc.subject.meshCyclooxygenase 2 Inhibitorsen_US
dc.subject.meshCyclooxygenase Inhibitors - Pharmacologyen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshFas Ligand Proteinen_US
dc.subject.meshFluorescent Dyes - Pharmacologyen_US
dc.subject.meshHumansen_US
dc.subject.meshIsoenzymes - Antagonists & Inhibitorsen_US
dc.subject.meshLiver Neoplasms - Drug Therapy - Pathologyen_US
dc.subject.meshMembrane Glycoproteins - Metabolismen_US
dc.subject.meshMembrane Proteinsen_US
dc.subject.meshNitrobenzenes - Pharmacologyen_US
dc.subject.meshProstaglandin-Endoperoxide Synthasesen_US
dc.subject.meshRna, Messenger - Metabolismen_US
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen_US
dc.subject.meshSulfonamides - Pharmacologyen_US
dc.titleSpecific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells.en_US
dc.typeArticleen_US
dc.identifier.emailLeung, WK:waikleung@hku.hken_US
dc.identifier.authorityLeung, WK=rp01479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid12792783-
dc.identifier.scopuseid_2-s2.0-0344275593en_US
dc.identifier.volume23en_US
dc.identifier.issue1en_US
dc.identifier.spage113en_US
dc.identifier.epage119en_US
dc.identifier.isiWOS:000183412300013-
dc.publisher.placeGreeceen_US
dc.identifier.scopusauthoridCheng, AS=7402075036en_US
dc.identifier.scopusauthoridChan, HL=16038785900en_US
dc.identifier.scopusauthoridLeung, WK=7201504523en_US
dc.identifier.scopusauthoridWong, N=7202836653en_US
dc.identifier.scopusauthoridJohnson, PJ=7405661637en_US
dc.identifier.scopusauthoridSung, JJ=35405352400en_US
dc.identifier.issnl1019-6439-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats